8-KLeadership Changes

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Mar 5, 2009)

Filed March 5, 2009For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on March 4, 2009, to report a change in its Board of Directors. Nancy-Ann DeParle resigned from her position on the Board, effective March 3, 2009. This departure is directly related to her significant new role in the federal government as Counselor to the President and Director of the White House Office for Health Reform. While the resignation itself is a standard corporate event, Ms. DeParle's appointment to such a high-profile position within the White House highlights the caliber of individuals who have served on Boston Scientific's board. Investors should note that this change does not appear to be performance-related for Boston Scientific, but rather a consequence of a key executive taking on a critical public service role. The company did not announce any immediate replacements for the vacant board seat in this filing.

Key Highlights

  • 1Nancy-Ann DeParle has resigned from Boston Scientific's Board of Directors.
  • 2Her resignation was effective on March 3, 2009.
  • 3The resignation is in connection with her appointment to a significant role in the White House.
  • 4Ms. DeParle will serve as Counselor to the President and Director of the White House Office for Health Reform.
  • 5This filing is primarily informational regarding a director's departure.
  • 6No immediate replacement for the board seat was announced in this filing.

Frequently Asked Questions

Nancy-Ann DeParle resigned from the Boston Scientific Board of Directors due to her appointment as Counselor to the President and Director of the White House Office for Health Reform.

Based on this 8-K filing, the resignation appears to be solely due to Ms. DeParle's new government role and not indicative of any internal issues with Boston Scientific's performance or governance. Her appointment to a high-profile federal position suggests her expertise is valued.

This 8-K filing does not state whether Boston Scientific will appoint a new director to fill the vacancy left by Ms. DeParle's resignation. Such decisions are typically made and announced by the company at a later date.

The White House Office for Health Reform is a key office responsible for advising the President on health care policy and driving the administration's health reform agenda. Ms. DeParle's role as Director indicates a significant responsibility in shaping national health policy.